Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evaxion Biotech ( (EVAX) ) just unveiled an update.
Evaxion Biotech has announced a significant advancement in its precision cancer vaccine concept using its AI-Immunology platform, which targets non-conventional ERV tumor antigens. The new preclinical data shows promising results, including strong T-cell responses and tumor growth inhibition in mice, marking a proof-of-concept milestone. This development could expand the use of cancer vaccines to patients unresponsive to traditional immunotherapies, highlighting Evaxion’s potential to enhance cancer treatment options and strengthen its position in the biotech industry.
More about Evaxion Biotech
Evaxion Biotech A/S is a pioneering TechBio company that utilizes its AI platform, AI-Immunology, to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. With a focus on personalized vaccines, the company is advancing a clinical-stage oncology pipeline and a preclinical infectious disease pipeline, aiming to address high unmet medical needs.
YTD Price Performance: -81.05%
Average Trading Volume: 54,918
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.03M
See more data about EVAX stock on TipRanks’ Stock Analysis page.
